智通财经APP讯，中国生物制药(01177)发布公告，CPX102是在IL-29的基础上，经蛋白质工程优化得到的雾化吸入溶液，属于III型干扰素的一种。目前集团正针对该项目在中国开展IIb期临床试验，用于治疗儿童呼吸道合胞病毒(RSV)感染。 CPX102并不直接杀伤或抑制病毒，而是通过诱导细胞表面受体，促使细胞生成抗病毒蛋白，进而抑制病毒的复制。此外，CPX102还能通过调节细胞毒性T淋巴细胞(CTL细胞)、自然杀伤细胞(NK细胞)、巨噬细胞等免疫细胞，激活自身天然免疫，从而起到抗病毒的作用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.